Kasabach-Merritt Phenomenon
- Kasabach-Merritt Phenomenon (KMP) is a rare consumptive coagulopathy that can be seen with rapidly enlarging vascular tumours , such as Kaposiform hemangioepitheliomas.
- It is thought to be due to sequestration of platelets and clotting factors within the the lesion resulting in disseminated intravascular coagulation.
- Treatment is directed towards (1) maintaining hemostasis and (2) addressing the underlying tumor.
- Transfusion of platelets or FFP should be administered due to symptoms (such as bleeding), and not based on laboratory values alone.
- Treatment modalities targeting the tumour include medical therapy (corticosteroids, interferon alpha, vincristine), embolization, or surgical excision.
Last updated October 10, 2022
